

Programme

The TOPRA 41st Spring Introductory Course: Introduction to Pharmaceutical Regulatory Affairs

20 - 23 May 2019

De Vere Selsdon Estate, 126 Addington Rd, South Croydon CR2 8YA

Monday 20 May 2019

Chairperson: Mike Robertson, Pharmaceutical Quality Matters Day Coordinator: Jayne Cook, Abbvie Ltd

8:30	Registration & Tea/coffee
09:00	Welcome & Introduction to the course Steve Brookes, <i>Biogen &</i> Samantha Alsbury, <i>TOPRA</i>
09:15	New Product Development, The European Regulatory Environment & the Role of Regulatory Affairs Steve Brookes, <i>Biogen</i>
10:20	Overview of the MAA Ruth Flynn, AbbVie Ltd
11:15	Tea/ coffee break
11:30	Chemical Development/Quality Brian Corrigan, MSD
12:30	Lunch
13:30	Pharmaceutical Development/Quality Brian Corrigan, MSD
14:30	Module 3. An Agency Perspective Mirza Catibusic, Health Products Regulatory Authority (HPRA)
15:30	Tea/ coffee break
15:45	Case Study 1. Chemistry & Pharmacy Sally Steeden, BioPharm Solutions Ltd
18:00	Close
20:00	Dinner in the restaurant

Tuesday 21 May 2019

Chairperson: Xavier Luriat, Consultancy
Day Coordinator: Bob Ibbotson, Lucis Consulting Ltd.

08:30	Understanding the Need for Non-Clinical Safety Studies Chris Powell, GlaxoSmithKline
09:30	The Importance of Pharmacokinetics & Pharmacodynamics in Drug Development & Registration Helen Walker, HW ClinPharm Ltd
10:30	Tea/ coffee break
10:45	The Components of the Non-Clinical Section of a Marketing Authorisation Application David Jones, Medicines and Healthcare products Regulatory Agency (MHRA)
11:45	Questions
12:00	Lunch
13:00	Clinical Drug Development, Paediatric Investigation Plans & the link with Regulatory Affairs Ian Dews, Envestia Ltd
14:00	The Regulation of Clinical Trials in Europe – An Agency Perspective Graham McNaughton, <i>MHRA</i>
14:55	Tea/ coffee break
15:10	The European Clinical Trials Process – Industry Perspective Shaila Choi, KKSC Solutions LTD
15:40	The Components of the Clinical Section of a Marketing Authorisation Application Jan Span, <i>Medicines Evaluation Board (MEB)</i>
16:25	Questions
16:30	Case Study 2: Non-Clinical & Clinical Development Claire Beggs, AbbVie Ltd
20:00	Dinner in the Phoenix Lounge & Team quiz

Chairperson: Sue Harris, ex-MHRA Day Coordinator: Niamh Lawler-Turner, *PharmaFind Ltd*

08:30	EU Procedures and the Factors for Success – My Experience as a Pharmaceutical Assessor and Unit Manager Sue Harris, ex -MHRA
09:30	The Centralised Procedure - Practical Industry Experience Natalie Schmidt, <i>Pfizer</i>
10:30	Tea/ coffee break
10:45	The Mutual Recognition Procedure & the Decentralised Procedure – Practical Industry Experience Pete Embley, Bionical EMAS
11:45	Generic Applications & Biosimilars Pete Embley, Bionical EMAS
12:30	Questions
12:45	Lunch
13:45	Regulatory Strategy Session Part 1: 1. Initial considerations – bigger picture & strategic thinking 2. Information protection 3. Think global 4. Regulatory/HTA advice Neil Roberts, Gilead Sciences International & David Kane, Vertex Pharmaceuticals (Europe) Ltd
14:45	Tea/ coffee break
15:00	Regulatory Strategy Session Part 2: 1. Paediatric development & PIPs 2. Orphans 3. Early access 4. Tradenames Neil Roberts, Gilead Sciences International & David Kane, Vertex Pharmaceuticals (Europe) Ltd
16:30	Case Study 3. Regulatory Strategy David Kana, Vertex Pharmacouticals (Europa) Ltd.
19:00	David Kane, Vertex Pharmaceuticals (Europe) Ltd Drinks reception in the Orangery
19:30	Dinner/ dance in the Sanderson

Thursday 23 May 2019

Chairperson: Susannah Clements, GSK Day Coordinator: Emma Holmes, *Medeor Consulting Ltd*

08:30	Lifecycle Management – Quality Isabel Zwart, <i>Biogen</i>
09:30	Lifecycle Management - Safety & Efficacy Avni Pandhi, <i>Biogen</i>
10:45	Tea/ coffee break
11:00	Product Information – Regulation of the SmPC, PIL & label Julia Coombes, MHRA
12:15	Accurate, Balanced, Clear? The ABC of Medicines Advertising Tannyth Cox, Prescription Medicines Code of Practice Authority
12:45	Lunch
13:45	Case Study 3. Variations Ming Ewe, Freeline Therapeutics
15:00	Tea/ coffee break
15:15	Health Technology Assessment: Why and where does the regulatory professional become involved? Sharon Gorman, <i>Pfizer</i>
16:00	An Introduction to Biotechnology & Advanced Therapy Medicinal Products Paul Smith, MetisRA Consulting Ltd
17:00	Questions and closing remarks Susannah Clements, GlaxoSmithKline